STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 50, Pages 15408-15413
Publisher
Proceedings of the National Academy of Sciences
Online
2015-11-26
DOI
10.1073/pnas.1512832112
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Positive feedback regulation of type I interferon by the interferon-stimulated gene STING
- (2015) F. Ma et al. EMBO REPORTS
- Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation
- (2014) Nora Pencheva et al. CELL
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Cyclic [G(2′,5′)pA(3′,5′)p] Is the Metazoan Second Messenger Produced by DNA-Activated Cyclic GMP-AMP Synthase
- (2013) Pu Gao et al. CELL
- Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice
- (2013) Mi Ryung Roh et al. MELANOMA RESEARCH
- STING Recognition of Cytoplasmic DNA Instigates Cellular Defense
- (2013) Takayuki Abe et al. MOLECULAR CELL
- cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING
- (2013) Andrea Ablasser et al. NATURE
- Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP
- (2013) Andrea Ablasser et al. NATURE
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
- (2013) J. J. Luke et al. ONCOLOGIST
- Cell-Specific Regulation of Nucleic Acid Sensor Cascades: a Controlling Interest in the Antiviral Response
- (2012) S. C. Stein et al. JOURNAL OF VIROLOGY
- STING Specifies IRF3 Phosphorylation by TBK1 in the Cytosolic DNA Signaling Pathway
- (2012) Y. Tanaka et al. Science Signaling
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells
- (2011) Zhiqiang Zhang et al. NATURE IMMUNOLOGY
- Neutrophils responsive to endogenous IFN-β regulate tumor angiogenesis and growth in a mouse tumor model
- (2010) Jadwiga Jablonska et al. JOURNAL OF CLINICAL INVESTIGATION
- IFI16 is an innate immune sensor for intracellular DNA
- (2010) Leonie Unterholzner et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Horizontal transfer of tumor DNA to endothelial cells in vivo
- (2009) J Ehnfors et al. CELL DEATH AND DIFFERENTIATION
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
- (2009) Hiroki Ishikawa et al. NATURE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started